vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and INSEEGO CORP. (INSG). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $48.4M, roughly 2.0× INSEEGO CORP.). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 1.0%, a 27.4% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 0.6%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $11.6M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 13.6%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Inseego Corp designs, manufactures and delivers advanced 5G and IoT solutions including mobile hotspots, edge computing devices, and cloud-based device management platforms. It primarily serves telecom operators, enterprise clients, and public sector customers across global markets.
DVAX vs INSG — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $48.4M |
| Net Profit | $26.9M | $469.0K |
| Gross Margin | — | 42.2% |
| Operating Margin | 22.4% | 2.7% |
| Net Margin | 28.4% | 1.0% |
| Revenue YoY | 17.7% | 0.6% |
| Net Profit YoY | 53.0% | 182.9% |
| EPS (diluted) | $0.21 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $48.4M | ||
| Q3 25 | $94.9M | $45.9M | ||
| Q2 25 | $95.4M | $40.2M | ||
| Q1 25 | $68.2M | $31.7M | ||
| Q4 24 | $72.0M | $48.1M | ||
| Q3 24 | $80.6M | $54.0M | ||
| Q2 24 | $73.8M | $51.6M | ||
| Q1 24 | $50.8M | $37.5M |
| Q4 25 | — | $469.0K | ||
| Q3 25 | $26.9M | $1.4M | ||
| Q2 25 | $18.7M | $507.0K | ||
| Q1 25 | $-96.1M | $-1.6M | ||
| Q4 24 | $7.0M | $-566.0K | ||
| Q3 24 | $17.6M | $9.0M | ||
| Q2 24 | $11.4M | $624.0K | ||
| Q1 24 | $-8.7M | $-4.5M |
| Q4 25 | — | 42.2% | ||
| Q3 25 | — | 41.6% | ||
| Q2 25 | — | 41.1% | ||
| Q1 25 | — | 47.3% | ||
| Q4 24 | — | 37.3% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 36.4% | ||
| Q1 24 | — | 35.3% |
| Q4 25 | — | 2.7% | ||
| Q3 25 | 22.4% | 4.7% | ||
| Q2 25 | 15.1% | 3.2% | ||
| Q1 25 | -34.7% | -1.3% | ||
| Q4 24 | -2.3% | 3.7% | ||
| Q3 24 | 12.5% | 1.9% | ||
| Q2 24 | 7.0% | 3.6% | ||
| Q1 24 | -35.0% | -7.9% |
| Q4 25 | — | 1.0% | ||
| Q3 25 | 28.4% | 3.1% | ||
| Q2 25 | 19.6% | 1.3% | ||
| Q1 25 | -141.0% | -5.0% | ||
| Q4 24 | 9.8% | -1.2% | ||
| Q3 24 | 21.8% | 16.6% | ||
| Q2 24 | 15.4% | 1.2% | ||
| Q1 24 | -17.2% | -11.9% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $0.21 | $0.03 | ||
| Q2 25 | $0.14 | $-0.03 | ||
| Q1 25 | $-0.77 | $-0.16 | ||
| Q4 24 | $0.07 | $0.62 | ||
| Q3 24 | $0.12 | $-0.06 | ||
| Q2 24 | $0.08 | $-0.02 | ||
| Q1 24 | $-0.07 | $-0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $24.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $-4.0M |
| Total Assets | $946.5M | $93.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.9M | ||
| Q3 25 | $160.2M | $14.6M | ||
| Q2 25 | $99.1M | $13.2M | ||
| Q1 25 | $51.7M | $35.1M | ||
| Q4 24 | $95.9M | $39.6M | ||
| Q3 24 | $119.3M | $12.0M | ||
| Q2 24 | $112.5M | $49.0M | ||
| Q1 24 | $132.0M | $12.3M |
| Q4 25 | — | $-4.0M | ||
| Q3 25 | $534.1M | $-7.7M | ||
| Q2 25 | $494.2M | $-10.5M | ||
| Q1 25 | $530.9M | $-13.0M | ||
| Q4 24 | $596.8M | $-12.9M | ||
| Q3 24 | $681.4M | $-85.1M | ||
| Q2 24 | $642.8M | $-101.8M | ||
| Q1 24 | $618.5M | $-105.6M |
| Q4 25 | — | $93.8M | ||
| Q3 25 | $946.5M | $85.8M | ||
| Q2 25 | $918.4M | $83.1M | ||
| Q1 25 | $945.9M | $93.0M | ||
| Q4 24 | $986.3M | $100.0M | ||
| Q3 24 | $1.1B | $113.4M | ||
| Q2 24 | $1.0B | $149.6M | ||
| Q1 24 | $986.6M | $122.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $12.0M |
| Free Cash FlowOCF − Capex | $32.6M | $11.6M |
| FCF MarginFCF / Revenue | 34.4% | 24.0% |
| Capex IntensityCapex / Revenue | 1.3% | 0.7% |
| Cash ConversionOCF / Net Profit | 1.26× | 25.50× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $12.0M | ||
| Q3 25 | $33.8M | $3.2M | ||
| Q2 25 | $23.4M | $-4.5M | ||
| Q1 25 | $-19.6M | $-3.5M | ||
| Q4 24 | $53.0M | $-14.2M | ||
| Q3 24 | $19.5M | $14.8M | ||
| Q2 24 | $10.7M | $27.6M | ||
| Q1 24 | $-16.7M | $5.2M |
| Q4 25 | — | $11.6M | ||
| Q3 25 | $32.6M | $3.1M | ||
| Q2 25 | $22.0M | $-4.7M | ||
| Q1 25 | $-23.6M | $-3.5M | ||
| Q4 24 | $49.5M | $-14.3M | ||
| Q3 24 | $18.1M | $14.8M | ||
| Q2 24 | $9.9M | $27.6M | ||
| Q1 24 | $-17.4M | — |
| Q4 25 | — | 24.0% | ||
| Q3 25 | 34.4% | 6.7% | ||
| Q2 25 | 23.0% | -11.6% | ||
| Q1 25 | -34.6% | -11.0% | ||
| Q4 24 | 68.8% | -29.7% | ||
| Q3 24 | 22.5% | 27.4% | ||
| Q2 24 | 13.5% | 53.5% | ||
| Q1 24 | -34.3% | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | 1.3% | 0.2% | ||
| Q2 25 | 1.5% | 0.5% | ||
| Q1 25 | 5.8% | 0.1% | ||
| Q4 24 | 4.8% | 0.1% | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.5% | 0.0% |
| Q4 25 | — | 25.50× | ||
| Q3 25 | 1.26× | 2.22× | ||
| Q2 25 | 1.25× | -8.81× | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | 1.65× | ||
| Q2 24 | 0.94× | 44.31× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
INSG
Segment breakdown not available.
